PROCEPT BioRobotics Corp. (PRCT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$21.66+7.39%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · PRCT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -11.5% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 34.8% |
Growth built into the price is above our model estimate.
The price assumes 46.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 29 industry peers
PRCT — credit agreement
Dated 2026-09-24
Entry into a Material Definitive Agreement On September 23, 2026, PROCEPT BioRobotics Corporation (the “Company”) entered into a Third Amendment to Loan and Security Agreement (the “Third Amendment”) with Canadian Imperial Bank of Commerce (“CIBC”), which amends the Loan and Security Agreement, dated as of October 6, 2022, by and between the Company and CIBC, as previously amended by the First Amendment to Loan and Security Agreement, dated as of June 1, 2023, and the Second Amendment to Loan…
Why it matters: The September loan amendment may affect debt costs or access to cash. The event summary does not give its terms.
Watch forThe full amendment terms show lower borrowing costs or looser loan limits than before.
Also watch forThe terms show higher borrowing costs, tighter loan limits, or added restrictions.
Why it matters: Q2 margin reached 66%, helped by a $2.9M tariff refund. A similar result without that refund would show pricing and costs held up.
Supportive ifFull-year gross margin is about 65% or higher, with no similar tariff refund cited as a key driver.
Worry ifFull-year gross margin falls below 65%, or the company cuts its margin goal.
Why it matters: The company completed enrollment in its prostate cancer study. A clear next update would show progress on this clinical program.
Watch forThe company shares an update from the named WATER IV study. The update includes follow-up data or a stated date for results.
Also watch forThe company reports a delay, a study change, or no further update in the next earnings report.
Why it matters: Revenue growth tests whether the company can meet its full-year goal. First-half revenue rose 19.7% from 2025.
Supportive ifFull-year 2026 revenue is $390M-$410M, with U.S. procedures of 54,000-56,000.
Worry ifFull-year revenue falls below $390M, or management cuts the range; U.S. procedures fall below 54,000.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$262 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $614 loss on $10,000 · 6.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,377 loss on $10,000 · 53.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company remains loss-making, and its cost goal is less certain. The Q2 loss was $11.3M.
Supportive ifFull-year adjusted EBITDA loss is $30M-$35M, as management guided in Q2.
Worry ifFull-year adjusted EBITDA loss tops $35M, or management cuts its guidance range.
Why it matters: More procedures can lift handpiece sales, while new systems grow the installed base. Q2 U.S. procedures rose 21% year over year.
Supportive ifQ3 U.S. procedures rise year over year, and HYDROS placements exceed the 65 systems delivered in Q2.
Worry ifQ3 U.S. procedures fall year over year, or HYDROS placements are below Q2's 65 systems.